  |
 |
        |
 |
 |
 |
 |
     |
|||||||||||||||||||||||||||||||||||||||||||||||||
 |
Conference Details : Topics |
  |
Register Online |
 |
|||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 Primary Care Network
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
|
Conference Details : Topics |
|
Register Online |
|
|||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Overview
This lecture will provide a review of epidemiology, acute stroke treatment strategies, overview of the major stroke studies, current stroke treatment guidelines, and global risk reduction strategies. Implementation and patient adherence strategies in the primary care setting will also be discussed.
Objectives
Name the top 3 modifiable risk factors for ischemic stroke
List 4 current treatment recommendations from the AHA/ASA Stroke Guidelines for survivors of ischemic stroke or TIA to prevent future events
Faculty
Bhuvaneswari K. Dandapani, MD
Vascular Neurologist
Director, Stroke Program
Holmes Regional Medical Center
Melbourne, FL
David S. Kountz, MD, FACP
Associate Professor of Medicine
Robert Wood Johnson
Medical School
New Brunswick, NJ
Overview
This course considers the growing complaint of insomnia in the primary care practice and offers practical approaches to diagnosis and treatment. With the immense importance of sleep, and the need to proactively address insomnia patients in the practice, this course will provide key steps to insomnia management leading to improved patient outcomes and overall health.
Objectives
Describe a patient-centered approach to the diagnosis of insomnia and development of a treatment plan
Apply the elements of a risk/benefit analysis for choosing a pharmacologic option to various patients at risk
Faculty
Gary Richardson, MD
Senior Research Scientist, Sleep Research Laboratory
Senior Staff Physician in Endocrinology
Henry Ford Hospital
Detroit, MI
Paul Doghramji, MD
Overview
The current use of lipid lowering therapy in clinical practice has fallen short of the recommendations of national guidelines. Clearly, not an easy venture when treating patients with dyslipidemia, many with multiple risk factors and many with resulting coronary events that may be preventable if patients were treated aggressively to meet the NCEP-ATP lll goals. This presentation will address the clinical challenges of goal attainment (lack of compliance, aggressive treatment by clinicians, not leaving patients 15 points from goals), and provide clinicians with the pathways and knowledge to help attain their patients to goal.
Objectives
Describe at least two challenges in treating dyslipidemia to NCEP-ATP III goals, implement strategies that will help to assess CHD risk accurately, and get patients to targeted goals
Identify patients at increased risk for cardiovascular events and develop a treatment plan with at least 2 lipid lowering strategies, including the use of multiple therapies, which will help these patients achieve guideline-based targets taking into consideration current lifestyle and pharmacologic treatment options available thus reducing overall cardiovascular risk
Faculty
Barry L. Hainer, MD
Professor and Director, Clinical Services
Medical University of South Carolina
Charleston, SC
Ronald A. Codario, MD, FACP
Clinical Instructor in Medicine
Thomas Jefferson University Hospital
Philadelphia, PA
Overview
Migraine is a chronic, debilitating disorder that affects approximately 28 million Americans of whom ~18% are women and ~6% are men. When compared to migraines that occur during other times of the month, menstrual migraine (MM) may last longer and be more severe, disabling, frequent, and more difficult to treat. This program will address the new advances in the understanding of MM, the role of hormones, and how to select an appropriate treatment based on individual patient characteristics.
Objectives
Recognize migraine in the differential diagnosis of headaches that impact patients ability to fully function in their daily activities and identify menstrual migraine in female patients
Identify management strategies for women with menstrual migraine including use of headache calendars, behavioral modifications and approaches to acute and preventive treatment
Faculty
Susan L. Hutchinson, MD
Associate Clinical Professor, Department of Family Medicine
University of California, Irvine
Director, Orange County Migraine and Headache Center
Irvine, CA
Lisa Mannix, MD
Overview
Human papillomavirus (HPV) is the most common newly acquired sexually transmitted infection in the United States. It is a necessary cause of cervical cancer and genital warts, and is associated with other anogenital and head and neck cancers, and recurrent respiratory papillomatosis. Prevention of HPV infection through prophylactic vaccination provides a safe and effective option to reduce the health burden associated with HPV-related diseases. Two vaccines have been developed: a quadrivalent HPV (6, 11, 16, 18) vaccine, approved by the US Food and Drug Administration (FDA), and a bivalent HPV (16, 18) vaccine, currently under FDA review. Both vaccines have demonstrated lasting efficacy against HPV-associated cervical disease and are generally well tolerated. This program will review the health consequences of HPV infection; provide an update on the safety and efficacy of HPV vaccines, including recent data on efficacy in mid-adult women, duration of protection, and cross-protection against nonvaccine HPV types; and evaluate the benefits of widespread HPV vaccination in preventing HPV-related diseases.
Objectives
Describe the epidemiology, natural history and consequences of HPV infection
Evaluate the anticipated benefits of widespread HPV vaccination in preventing cervical and anogenital cancers, genital warts, and other HPV-related diseases
Faculty
Gregory Brotzman, MD
Professor of Family and Community Medicine
Medical College of Wisconsin
Milwaukee, WI
Martin C. Mahoney, MD, PhD
Director, Cancer Prevention & Detection Center
Roswell Park Cancer Institute
Associate Professor of Family Medicine
State University of New York at Buffalo
Buffalo, NY
Overview
An estimated 1 million cases of herpes zoster (shingles) occur annually in the United States. The incidence and severity of herpes zoster increase with advancing age to produce substantial negative effects on quality of life, activities of daily living, neuropsychological functioning, and social status, resulting in significant morbidity in older adults. While antiviral therapy reduces the incidence and severity of herpes zoster, it does not reliably prevent postherpetic neuralgia (PHN), the most common and debilitating clinical sequela of herpes zoster. Herpes zoster vaccination has been demonstrated to reduce the incidence of the disease and its complications. Clinical trial data have demonstrated significant reductions in the incidence of herpes zoster and PHN, as well as overall reductions in the burden of disease.
Objectives
Review the epidemiology and public health burden of herpes zoster and its most common complication, postherpetic neuralgia (PHN)
Discuss the benefits and limitations of current pharmacotherapies for herpes zoster and Postherpetic neuralgia (PHN), and evaluate clinical trial data on the efficacy and safety of herpes zoster vaccination
Faculty
Katherine E. Galluzzi, DO, FACOFP
Professor and Chairperson
Department of Geriatrics
Philadelphia College of Osteopathic Medicine
Philadelphia, PA
John W. Gnann, Jr., MD
Professor of Medicine, Pediatrics, and Microbiology
Department of Medicine, Division of Infectious Diseases
University of Alabama at Birmingham
Birmingham VA Medical Center
Birmingham, AL
Overview
ÒMore Than Skin Deep: Clinical Strategies for Acne Vulgaris and Actinic KeratosisÓ is a continuing medical education program that aims to bridge some of the existing professional practice gaps that primary care clinicians may have regarding common dermatologic problems. This program will educate clinicians in the primary care setting about the prevalence, impact, diagnosis, and treatment of both acne vulgaris and actinic keratosis.
Objectives
Confidently diagnose patients presenting with the basic dermatologic conditions of acne vulgaris and actinic keratosis
Identify the most commonly used treatments for acne vulgaris and actinic keratosis
Faculty
Seth Orlow, MD, PhD
Chair, Department of Dermatology
Samuel Weinberg Professor of Pediatric Dermatology
Professor of Cell Biology and Pediatrics
New York University School of Medicine
New York, NY
Paul J. Honig, MD
Emeritus Professor of Pediatrics and Dermatology
The Children's Hospital of Philadelphia
Philadelphia, PA
Overview
Chronic Constipation is a multi-symptom gastrointestinal motility disorder that negatively impacts the lives of approximately 33 million Americans. Due to the overlap in symptoms reported by patients with irritable bowel syndrome-constipation and chronic constipation, clinicians often find it challenging to differentiate between the two. With a changing landscape of therapeutic options available, it is imperative that clinicians be able to establish and accurate diagnosis so the proper foundation is provided for determining initial therapy and developing a treatment plan.
Objectives
Differentiate chronic constipation from other functional bowel disorders
Identify the therapies that can be used to treat chronic constipation and other functional bowel disorders
Faculty
Lin Chang, MD
Co-Director
Associate Professor of Medicine
Division of Digestive Diseases
Center for Neurovisceral Sciences & Women's Health
David Geffen School of Medicine UCLA
Los Angeles, CA
Lawrence R. Schiller, MD, FACP, FACG
Program Director
Gastroenterology Fellowship
Baylor University Medical Center
Dallas, TX
Overview
Allergic rhinitis (AR) is the most common allergic condition in the US, affecting nearly 40 million people. Although AR is associated with significant comorbidities, current therapies have proven only modestly successful. Allergic Rhinitis and Its Comorbidities: A Serious Challenge to the Health Care Professional will provide primary care physicians with practical, evidence-based solutions to the challenges of managing AR, with particular emphasis on finding effective treatments and ensuring patient compliance. Two nationally recognized allergy/immunology experts will lead each 75-minute presentation with 60 minutes of didactic lectures and case history presentation, and a 15-minute question-and-answer session. Interactive discussion and a dynamic audience response system will also be integrated into the session.
Objectives
Describe key clinical characteristics of allergic rhinitis, its associated comorbidities, and its impact on patient health and quality of life
Identify barriers to treatment success of allergic rhinitis (treatment-related, physician-related, and patient-related barriers) and adequate control of symptoms, and devise strategies for overcoming those barriers
Faculty
Ketan K. Sheth, MD, MBA
Private Practice
Lafayette Allergy and Asthma Clinic
Adjunct Associate Professor Clinical Pharmacy
Purdue University
Clinical Assistant Professor of Pediatrics
Indiana University School of Medicine
Lafayette, Indiana
Overview
Hypogonadism affects at least 20% of US men aged 50 years and older but is both under reported and under diagnosed. This program will explore the importance of hypogonadism and its comorbidities as a major health issue, review accurate diagnosis, discuss goals of treatment, and review available treatment options.
Objectives
Recognize that low serum testosterone is far more than a sexual dysfunction issue, acknowledge its association with other serious health conditions, such as metabolic syndrome, hypertension, renal failure, diabetes, and dyslipidemia, and have the improved ability to make an accurate diagnosis, as well as, describe the goals and benefits of TRT therapy and identify common misconceptions regarding the risks
Describe the benefits and limitations of different available delivery systems for TRT and emphasize the importance of regular patient monitoring
Faculty
Glenn Cunningham, MD
Professor of Medicine and Professor of Molecular and Cellular Biology
Baylor College of Medicine
Houston, Texas
Overview
Four million people in the United States suffer from neuropathic pain, a condition that is often difficult to diagnose. This session, Clinical Conversation: Diagnosis & Treatment of Neuropathic Pain will address practical ways primary care physicians can improve recognition and treatment of neuropathic pain.
Objectives
Recognize signs and symptoms of neuropathic pain to increase identification of patients with neuropathic pain
Evaluate available treatment options for neuropathic pain and their appropriateness for your patient population to improve outcomes in these patients
Faculty
M. Susan Burke, MD, FACP
Clinical Assistant Professor of Medicine
Thomas Jefferson University
Philadelphia, Pennsylvania
Director, Internal Medicine Clinical Care Center
Lankenau Hospital
Wynnewood, PA
Bill McCarberg, MD
Clinical Assistant Professor of Medicine, Thomas Jefferson University in Philadelphia, PA, and Director, Lankenau Internal Medicine Clinical Care Center, Lankenau Hospital
Wynnewood, PA
Overview
Rheumatoid arthritis (RA) is a complex immunologic and chronic inflammatory disease that affects more than 2 million people in the United States. Characterized by inflammation of the joints, periarticular bone resorption and cartilage destruction, RA is also an inherently aggressive, systemic disease that leaves patients vulnerable to comorbidities such as cardiovascular disease, osteoporosis, lymphoma, infection, and stroke. While primary care clinicians may not directly treat the disease long term, they are the first to come in contact with potential RA patients. Therefore it is important for all clinicians to be aware of the necessary steps in RA diagnostic and treatment modalities.
Objectives
Identify 3 early warning signs of rheumatoid arthritis (RA)
Describe current and evolving treatment options for RA, and be alert to monitoring and side effects related to these therapies
Faculty
Arthur Weaver, MD, MS, FACP, MACR
Arthur Kavanaugh, MD
Professor of Medicine
The University of California at San Diego, School of Medicine
San Diego, CA
Overview
Optimal Use of Analgesics in the Management of Osteoarthritis Pain will provide an evidence-based, guideline-based review of treatment options for managing osteoarthritis pain. Video-vignette, case-based learning will be used to illustrate education from expert presentations and guidelines. Special emphasis will be placed on physician-patient communication regarding pain management.
Objectives
Implement strategies for patient communication and education for management of OA pain and utilize pharmacologic and nonpharmacologic therapies for pain management according to guideline recommendations
Describe patient risk factors which could interact with various pain relief medications
Faculty
Javier C. Waksman, MD, DABT, FACMT
Associate Professor
Department of Medicine
University of Colorado Denver
Aurora, Colorado
Michael J. Cawley, PharmD
Associate Professor of Clinical Pharmacy
Philadelphia College of Pharmacy
Philadelphia, Pennsylvania
Overview
TBD
Objectives
Faculty